Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 5,467 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumor Malignancies, Cancer Clear all

Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Interventions: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion; Drug
Lead sponsor: RasCal Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Nashville, Tennessee

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: psychosocial assessment and care; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2005
U.S. locations: 26
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: MG 98; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors
Interventions: 609A; Drug
Lead sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: monoclonal antibody A27.15, monoclonal antibody E2.3; Biological
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Non-Hodgkin's Lymphoma,, Solid Tumors
Interventions: PPI-2458; Drug
Lead sponsor: PRAECIS Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more

Conditions: Cancer, Tumor
Interventions: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neuroblastoma, Pediatric Solid Tumor
Interventions: Tissue collection, GVAX vaccine, Nivolumab, Ipilimumab; Procedure · Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 1 Year and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dietary counseling via computer, dietary counseling via nutritionist, combined computer and nutritionist, physical activity counseling via computer; Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 621 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Aurora, Colorado • Eugene, Oregon • Portland, Oregon

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cyclosporine, irinotecan hydrochloride, phenobarbital; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Actinic Keratoses, Skin Neoplasms
Interventions: Aminolevulinic Acid, Vehicle; Drug · Other
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Miami, Florida + 4 more

Conditions: Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma
Interventions: CX-4945 oral formulation; Drug
Lead sponsor: Cylene Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: exercise intervention, counseling intervention, educational intervention, complementary or alternative medicine procedure; Behavioral · Other · Procedure
Lead sponsor: Montclair State University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Montclair, New Jersey

Conditions: Solid Tumor
Interventions: Cetuximab, Cisplatin, 5 - Fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more

Conditions: Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions: BB-1701; Drug
Lead sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Nashville, Tennessee • Fairfax, Virginia

Conditions: Tumors, Neoplasms
Interventions: TTI-237; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Lexington, Kentucky • Cleveland, Ohio • Nashville, Tennessee

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions: FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab; Drug · Combination Product
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more

Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions: INBRX-105 - PDL1x41BB antibody, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 23
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more

Conditions: Hepatic Impairment, Solid Tumor, Cancer
Interventions: Tivantinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Hackensack, New Jersey

Conditions: Neoplasm, Diarrhea
Interventions: Irinotecan, Cefpodoxime; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 20 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Advanced Solid Tumor
Interventions: STX-001, Keytruda®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more

Conditions: Advanced Solid Tumor
Interventions: Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea; Drug · Procedure
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvocidib, gemcitabine hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

MG98 in Treating Patients With Advanced Solid Tumors

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

GVAX Plus Checkpoint Blockade in Neuroblastoma

Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Dose-escalation Study of Oral CX-4945

Promoting Physical Activity In After-School Programs for Urban Adolescents

Study in Advanced Solid Tumors

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment

Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors